{"id":"https://openalex.org/W2002098103","doi":"https://doi.org/10.1016/j.neuropharm.2004.01.016","title":"Erratum to \u201cIdentification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist\u201d [Neuropharmacology 46 (2004) 133\u2013149]","display_name":"Erratum to \u201cIdentification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist\u201d [Neuropharmacology 46 (2004) 133\u2013149]","alternate_titles":[],"publication_year":2004,"publication_date":"2004-02-27","ids":{"openalex":"https://openalex.org/W2002098103","doi":"https://doi.org/10.1016/j.neuropharm.2004.01.016","mag":"2002098103"},"language":"en","primary_location":{"id":"doi:10.1016/j.neuropharm.2004.01.016","doi":"https://doi.org/10.1016/j.neuropharm.2004.01.016","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2004.01.016","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2002098103"],"child_works_count":0,"type":"erratum","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037876897","display_name":"Martin J. Gunthorpe","orcid":"https://orcid.org/0000-0002-0216-1735","observed_orcids":["https://orcid.org/0000-0002-0216-1735"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"M.J. Gunthorpe","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002025767","display_name":"Harshad K. Rami","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"H.K. Rami","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110000680","display_name":"Jeffrey C. Jerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J.C. Jerman","raw_affiliation_strings":["Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111827065","display_name":"Darren Smart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Smart","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023756649","display_name":"Catherine H. Gill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C.H. Gill","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083616069","display_name":"Ellen M. Soffin","orcid":"https://orcid.org/0000-0002-2496-7174","observed_orcids":["https://orcid.org/0000-0002-2496-7174"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"E.M. Soffin","raw_affiliation_strings":["Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064097741","display_name":"Sara Luis Hannan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S.Luis Hannan","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028076388","display_name":"Sarah C. Lappin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S.C. Lappin","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052228694","display_name":"Julie Egerton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Egerton","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"G.D. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G.D. Smith","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054492220","display_name":"Angela Worby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Worby","raw_affiliation_strings":["Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049659463","display_name":"L. Howett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"L. Howett","raw_affiliation_strings":["Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047677418","display_name":"Davina E. OWEN","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Owen","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088288221","display_name":"S. Nasir","orcid":"https://orcid.org/0009-0001-0839-9058","observed_orcids":["https://orcid.org/0009-0001-0839-9058"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Nasir","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019383039","display_name":"Ceri H. Davies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C.H. Davies","raw_affiliation_strings":["Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111214806","display_name":"M. THOMPSON","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Thompson","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111862521","display_name":"Paul A. Wyman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P.A. Wyman","raw_affiliation_strings":["Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry-CEDD, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018828484","display_name":"Andrew D. Randall","orcid":"https://orcid.org/0000-0001-8852-3671","observed_orcids":["https://orcid.org/0000-0001-8852-3671"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A.D. Randall","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":null,"display_name":"J.B. Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J.B. Davis","raw_affiliation_strings":["Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and GI-CEDD New Frontiers Science Park, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5037876897"],"corresponding_institution_ids":["https://openalex.org/I188950975"],"apc_list":{"value":4300,"currency":"USD","value_usd":4300},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"46","issue":"6","first_page":"905","last_page":"905"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11204","display_name":"Ion Channels and Receptors","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2809","display_name":"Sensory Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11204","display_name":"Ion Channels and Receptors","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2809","display_name":"Sensory Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10196","display_name":"Pain Mechanisms and Treatments","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11584","display_name":"Biochemical Analysis and Sensing Techniques","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2916","display_name":"Nutrition and Dietetics"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vanilloid-receptor","display_name":"vanilloid receptor","score":0.8650000095367432},{"id":"https://openalex.org/keywords/trpv1","display_name":"TRPV1","score":0.984000027179718},{"id":"https://openalex.org/keywords/receptor-antagonists","display_name":"receptor antagonists","score":0.7369999885559082},{"id":"https://openalex.org/keywords/capsaicin-receptor","display_name":"capsaicin receptor","score":0.7379999756813049}],"concepts":[{"id":"https://openalex.org/C128188215","wikidata":"https://www.wikidata.org/wiki/Q3026765","display_name":"Neuropharmacology","level":2,"score":0.8563539981842041},{"id":"https://openalex.org/C160145004","wikidata":"https://www.wikidata.org/wiki/Q413209","display_name":"TRPV1","level":4,"score":0.8263167142868042},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6629030108451843},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5548141598701477},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5010356903076172},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.34814372658729553},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3214978873729706},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.31470322608947754},{"id":"https://openalex.org/C155164980","wikidata":"https://www.wikidata.org/wiki/Q304043","display_name":"Transient receptor potential channel","level":3,"score":0.29543060064315796},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22854569554328918},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13955193758010864}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.neuropharm.2004.01.016","doi":"https://doi.org/10.1016/j.neuropharm.2004.01.016","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.neuropharm.2004.01.016","pdf_url":null,"source":{"id":"https://openalex.org/S160566677","display_name":"Neuropharmacology","issn_l":"0028-3908","issn":["0028-3908","1873-7064"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropharmacology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.6240000128746033,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1963531856","https://openalex.org/W2804642002","https://openalex.org/W2155595035","https://openalex.org/W4367312675","https://openalex.org/W2981890266","https://openalex.org/W2107756388","https://openalex.org/W2176081232","https://openalex.org/W2080762869","https://openalex.org/W1151386647"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2002098103","counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
